Bristol-Myers Squibb completed a public offering of $1 billion aggregate principal amount of 5.750% Notes due 2031, $1 billion aggregate principal amount of 5.900% Notes due 2033, $1.25 billion aggregate principal amount of 6.250% Notes due 2053, and $1.25 billion aggregate principal amount of 6.400% Notes due 2063, with the net proceeds intended for general corporate purposes and the financing of the proposed acquisition of Mirati Therapeutics.